HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) View Appendix All Versions of this Article: j.jacc.2007.03.025v1 49/19/1982    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (35) Citing Articles via Google Scholar Google Scholar Articles by Bhatt, D. L. Search for Related Content PubMed Articles by Bhatt, D. L.

EXPEDITED REVIEW

Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial

Deepak L. Bhatt, MD, FACC^_*,_*, Marcus D. Flather, MD, Werner Hacke, MD, Peter B. Berger, MD, FACC, Henry R. Black, MD^||, William E. Boden, MD, FACC^¶, Patrice Cacoub, MD^#, Eric A. Cohen, MD^_**, Mark A. Creager, MD, FACC, J. Donald Easton, MD, Christian W. Hamm, MD, FACC, Graeme J. Hankey, MD^||||, S. Claiborne Johnston, MD, PhD^¶¶, Koon-Hou Mak, MD, FACC^##, Jean-Louis Mas, MD^_***, Gilles Montalescot, MD, PhD, Thomas A. Pearson, MD, FACC, P. Gabriel Steg, MD, FACC, Steven R. Steinhubl, MD, FACC^||||||, Michael A. Weber, MD, FACC^¶¶¶, Liz Fabry-Ribaudo, MSN, RN^_*, Tingfei Hu, MS^_*, Eric J. Topol, MD, FACC^###, Keith A.A. Fox, MBChB^_**** for the CHARISMA Investigators

^_* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom
Department of Neurology, University of Heidelberg, Heidelberg, Germany
Geisinger Center for Health Research, Danville, Pennsylvania
^|| New York University School of Medicine, New York, New York
^¶ Division of Cardiology, Kaleida Healthcare, Buffalo, New York
^# Department of Internal Medicine, Hopital Pitie-Salpetriere, Paris, France
^_** Division of Cardiology, Sunnybrook and Women’s College Health Science Centre, Toronto, Canada
Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Department of Neurology, Rhode Island Hospital and Brown University, Providence, Rhode Island
Department of Cardiology, Kerckhoff-Klinik Center, Bad Nauheim, Germany
^|||| Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia
^¶¶ Department of Neurology, University of California San Francisco, San Francisco, California
^## Gleneagles Medical Centre, Singapore
^_*** Department of Neurology and Stroke Unit, Sainte-Anne Hospital, Paris, France
Institut de Cardiologie — Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
Department of Community & Preventive Medicine, University of Rochester School of Medicine, Rochester, New York
Service de Cardiologie, Hôpital Bichat, Paris, France
^|||||| Division of Cardiology, University of Kentucky, Lexington, Kentucky
^¶¶¶ SUNY Downstate Medical Center College of Medicine, Brooklyn, New York
^### Case Western Reserve University, Cleveland, Ohio
^_**** University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Manuscript received December 4, 2006; revised manuscript received March 16, 2007, accepted March 20, 2007.

^_* Reprint requests and correspondence: Dr. Deepak L. Bhatt, Associate Director, Cardiovascular Coordinating Center, Staff, Cardiac, Peripheral, and Carotid Intervention, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195. (Email: bhattd{at}ccf.org).

Objectives: The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD).

Background: Dual antiplatelet therapy with clopidogrel plus aspirin has been validated in the settings of acute coronary syndromes and coronary stenting. The value of this combination was recently evaluated in the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, where no statistically significant benefit was found in the overall broad population of stable patients studied.

Methods: We identified the subgroup in the CHARISMA trial who were enrolled with documented prior MI, ischemic stroke, or symptomatic PAD.

Results: A total of 9,478 patients met the inclusion criteria for this analysis. The median duration of follow-up was 27.6 months. The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7.3% versus 8.8% (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.72 to 0.96, p = 0.01). Additionally, hospitalizations for ischemia were significantly decreased, 11.4% versus 13.2% (HR 0.86, 95% CI 0.76 to 0.96, p = 0.008). There was no significant difference in the rate of severe bleeding: 1.7% versus 1.5% (HR 1.12, 95% CI 0.81 to 1.53, p = 0.50); moderate bleeding was significantly increased: 2.0% versus 1.3% (HR 1.60, 95% CI 1.16 to 2.20, p = 0.004).

Conclusions: In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke, or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin. Such patients may benefit from intensification of antithrombotic therapy beyond aspirin alone, a concept that future trials will need to validate. (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA]; http://clinicaltrials.gov/ct/show/NCT00050817?order=1; NCT00050817 [ClinicalTrials.gov] )

Abbreviations and Acronyms   CI = confidence interval   HR = hazard ratio   MI = myocardial infarction   PAD = peripheral arterial disease

This article has been cited by other articles:

				J. Sullivan and N. Amarshi Dual antiplatelet therapy with clopidogrel and aspirin Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1134 - 1143. [Abstract] [Full Text] [PDF]

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF]

				V. Thijs, R. Lemmens, and S. Fieuws Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092. [Abstract] [Full Text] [PDF]

				M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review Stroke, May 1, 2008; 39(5): 1638 - 1646. [Abstract] [Full Text] [PDF]

				M. R. BAKHRU and D. L. BHATT INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295. [Abstract] [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 944 - 955. [Full Text] [PDF]

				C. M. Wittgen Limb Ischemia: Medical Therapy Trial Update Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2008; 20(1): 38 - 42. [Abstract] [PDF]

				F. M. Gengo, M. Rainka, M. Robson, M. F. Gengo, A. Forrest, M. Hourihane, and V. Bates Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events J. Clin. Pharmacol., March 1, 2008; 48(3): 335 - 343. [Abstract] [Full Text] [PDF]

				D. L. Bhatt Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis N. Engl. J. Med., November 15, 2007; 357(20): 2078 - 2081. [Full Text] [PDF]

				J. M. Gebel Jr. The CAPRIE-Like Subgroups of CHARISMA: A CAPRIEciously Biased Analysis of an unCHARISMAtic Truth J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1704 - 1704. [Full Text] [PDF]

				D. L. Bhatt, M. D. Flather, and on behalf of the CHARISMA Executive Committee and Reply J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1704 - 1705. [Full Text] [PDF]

				T. H. Wang, D. L. Bhatt, K. A.A. Fox, S. R. Steinhubl, D. M. Brennan, W. Hacke, K.-H. Mak, T. A. Pearson, W. E. Boden, P. G. Steg, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial Eur. Heart J., September 2, 2007; 28(18): 2200 - 2207. [Abstract] [Full Text] [PDF]

				A. A. Bavry and D. L. Bhatt Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor? Circulation, August 14, 2007; 116(7): 696 - 699. [Full Text] [PDF]